All other chemicals and reagents used in the study were of analytical grade. Matrix tablets of LAMI were prepared using various proportions of HPMC and a combination of HPMC and PEO as drug retarding polymers employing direct compression method. The drug, polymer(s) and all other excipients were sifted through 425 μm sieve (ASTM mesh no 40) and mixed uniformly. The dry blend was then blended with Aerosil and talc followed by magnesium stearate. The lubricated powder blends were characterized for drug content. The lubricated powder

blends were directly compressed on 16-station tablet compression machine (Cadmach Machinery Co, Ahmedabad, India) using 9 mm flat faced round (FFR) punches. Three batches were prepared for each formulation and compressed into 200 tablets from every batch for the characterization study. The drug content of the prepared matrix tablets

SAR405838 order was determined in triplicate. For each batch, 20 tablets were taken, weighed and finely powdered. An Sorafenib purchase accurately weighed 300 mg of this powder was transferred to a 100 ml of pH 7.0 phosphate buffer, mixed for 10 min under sonication (Power sonic 505, HWASHIN Technology Co., Korea) and filtered through 0.45 μ (Millipore, India) filter. The sample was analysed after making appropriate dilutions using a UV spectrophotometer (UV-1700 E 23, Schimadzu, Japan) at 271.5 nm against blank.24 The weight variation was determined by taking 20 tablets using an Carnitine palmitoyltransferase II electronic balance (ER182A, Mettler Toledo, Switzerland). Tablet hardness was determined for 10 tablets using a Monsanto tablet hardness tester (MHT-20, Campbell Electronics, Mumbai, India). Friability was determined by testing 10 tablets in a friability tester (FTA-20, Campbell Electronics, Mumbai, India) for 300 revolutions at 25 rpm. Moisture uptake studies on the powder blends and tablets was carried out at room temperature (30 ± 5 °C) and various relative humidity (RH) conditions such as 33%, 54% and 90% RH for assessing the varying environmental conditions during the manufacture process and storage.25 The

humid conditions of 33%, 54% and 90% RH were maintained by employing the saturated solutions of magnesium chloride, sodium dichromate potassium nitrate respectively. These solutions were transferred separately into three desiccators and allowed them for 24 h for saturation inside the chamber. Then accurately weighed powder blends and all the prepared tablets formulations were spread on petri plates and placed in each desiccator. The samples were weighed at 24, 48, 72, 96 and 120 h and the percent moisture uptake was determined. The in vitro dissolution studies were performed up to 14 h using the USP type I dissolution apparatus (Disso-2000, Labindia, Mumbai, India) at 100 rpm. The dissolution medium consisted of 900 ml of pH 7.0 phosphate buffer maintained at 37 ± °C as developed by Hwisa et al.